SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivimed Labs reports Profit after tax of Rs -221.55 Mln, in the September 2022 quarter

21 Nov 2022 Evaluate
The sales for the September 2022 quarter moved down to Rs. 391.82 millions as compared to Rs. 510.44 millions during the year-ago period.The Net Loss for the quarter ended September 2022 is Rs. -221.55 millions as compared to Net Loss of Rs. -234.59 millions of corresponding quarter ended September 2021 Operating profit Margin for the quarter ended September 2022 improved to -95.61% as compared to -107.43% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 391.82 510.44 -23.24 865.46 1133.42 -23.64 2183.67 2100.46 3.96
Other Income 1.49 1.43 4.20 2.30 10.58 -78.26 12.59 60.75 -79.28
PBIDT -95.61 -107.43 -11.00 -180.09 9.91 -1917.26 -79.58 278.64 -128.56
Interest 87.90 85.50 2.81 180.47 179.96 0.28 395.27 414.92 -4.74
PBDT -183.51 -192.93 -4.88 -360.56 -170.05 112.03 -474.85 -136.28 248.44
Depreciation 38.04 41.66 -8.69 80.37 85.17 -5.64 174.50 157.95 10.48
PBT -221.55 -234.59 -5.56 -440.93 -255.22 72.76 -649.35 -294.23 120.69
TAX 0.00 0.00 0.00 -0.52 0.00 0.00 28.17 -2.34 -1303.85
Deferred Tax 0.00 0.00 0.00 -0.52 0.00 0.00 28.17 0.00 0.00
PAT -221.55 -234.59 -5.56 -440.41 -255.22 72.56 -677.52 -291.89 132.11
Equity 165.83 165.83 0.00 165.83 165.83 0.00 165.83 165.83 0.00
PBIDTM(%) -24.40 -21.05 15.94 -20.81 0.87 -2480.03 -3.64 13.27 -127.47

Vivimed Labs Share Price

7.79 0.37 (4.99%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×